蓝灯app下

                                  A clinical-stage gene therapy company striving to halt or reverse
                                  disease with a single dose.

                                  We are AVROBIO

                                  蓝灯app下

                                  • Overview
                                  • Press Releases
                                  • Events & Presentations
                                  • Corporate Governance
                                  • SEC Filings
                                  • Stock Information
                                  • Analyst Coverage
                                  • FAQs

                                  蓝灯app下

                                  蓝灯app下

                                  Our mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato® gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

                                  Sign up for email alerts

                                  Stock Chart

                                  国内苹果怎么上twitter

                                  Data Provided by Refinitiv. Minimum 15 minutes delayed.

                                  Events & Presentations

                                  Apr 9, 2024

                                  AVROBIO at Wells Fargo’s Biotech Corporate Access Day – San Francisco

                                  Apr 7, 2024

                                  AVROBIO at Wells Fargo’s Biotech Corporate Access Day -- Boston

                                  Our News Latest press releases

                                  Jul 08, 2024

                                  AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

                                  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2024-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

                                  Read More

                                  Jul 06, 2024

                                  免费海外appleid账号密码共享-苹果id分享网:2021-4-20 · 苹果id分享网提供国外ios公共免费苹果账号密码，有免费的苹果美国id及共享香港、台湾、日本、韩国等海外地区appleid账号密码大全 国外苹果ID账号分享，AppleID定期更新解锁 2021年最新 35015 1980 分享 苹果ID分享 国外苹果id账号分享，包含有 ...

                                  First patient dosed in AVROBIO’s global Phase 1/2 clinical trial of AVR-RD-02   for Gaucher disease type 1 Second patient dosed in investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 6, 2024-- AVROBIO, Inc.

                                  国内iphone怎么上推特

                                  国内iphone怎么上推特

                                  国内上twitter教程

                                  AVROBIO co-founder and veteran gene and cell therapy pioneer Kim Warren to retire July 31, 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 29, 2024-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today

                                  Read More

                                  安卓上推特教程

                                  See All

                                  蓝灯app下

                                  Chris Brinzey
                                  Westwicke Partners for AVROBIO
                                  Phone: 339-970-2843
                                  Email: chris.brinzey@westwicke.com

                                  蓝灯app下

                                  We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.